Press Release: Incyte to Report First Quarter Financial Results

Dow Jones
04-10

Incyte to Report First Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--April 10, 2025-- 

Incyte (Nasdaq: INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 29, 2025.

The schedule for the press release and conference call/webcast is as follows:

   -- Q1 2025 Press Release: April 29, 2025 at 7:00 a.m. ET 
 
   -- Q1 2025 Conference Call: April 29, 2025 at 8:00 a.m. ET 
 
   -- Domestic Dial-In Number: 877-407-3042 
 
   -- International Dial-In Number: 201-389-0864 
 
   -- Conference ID Number: 13753168 

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13753168.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250410696945/en/

 
    CONTACT:    Media 

media@incyte.com

Investors

ir@incyte.com

 
 

(END) Dow Jones Newswires

April 10, 2025 08:02 ET (12:02 GMT)

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10